Hang Quach

Hematology — St Vincent's Hospital, Australia

LeadR Profile

Hang Quach St Vincent's Hospital Australia
2 010 ScienceLeadR Reputation 2010
Network Map

Hematology

Subspecialties: Oncology - Immunology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Hang Quach is a haematologist specialising in multiple myeloma. She is Professor of Haematology at the University of Melbourne and serves as Head of Department and Director of Research at St Vincent’s Hospital Melbourne (SVHM). She leads the SVHM Myeloma Program and oversees its clinical trials unit, which runs over 135 active phase I to III clinical trials investigating novel therapies in haematological malignancies.

Professor Quach currently serves as Co-Chair of the Myeloma Working Group of the Australasian Lymphoma and Leukaemia Group (ALLG), Deputy Chair of the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia, and a Steering Committee Member of the Australasian Myeloma Research Consortium (AMaRC).

Her clinical research focuses on novel therapeutics for multiple myeloma and the development of regionally relevant trials that translate into practice across the Asia-Pacific (APAC) region

Organizations

Career arc: 2005 - 2026

Source: PubMed

University of Melbourne

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 428

Citations

Citations: 12 564 1st author: 57 Last author: 50 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.
dexamethasone, leukemia, multiple myeloma, lenalidomide, transplants, therapeutics, frailty
Leukemia20260
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.
cells, microscopy, electron, scanning transmission, stem cells, maintenance, drug-related side effects and adverse reactions, multiple myeloma, lenalidomide, transplants, therapeutics, cell transplantation, stem cell transplantation, transplantation
Br J Haematol20260
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.
dexamethasone, leukemia, survival analysis, multiple myeloma, lenalidomide, transplants, therapeutics
Leukemia20260
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
safety, dexamethasone, disease progression, drug-related side effects and adverse reactions, multiple myeloma, lenalidomide, therapeutics, infections
Lancet Top journal20264
Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.
registries, multiple myeloma, cytogenetics
Br J Haematol20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 21
Phase 2 10
Phase 1 4
Phase 1/Phase 2 4
N/A 2

By status:

Completed 22
Active not recruiting 10
Recruiting 3
Terminated 3
Unknown 3

By type:

Interventional 39
Observational 2

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 1
multicentricup10 34

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Gammagard Liquid (Immune Globulin Infusion 10 ) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480 — cells, safety, pharmaceutical preparations, drug therapy, immunoglobulins, multiple myeloma, therapeutics, globulins, b-lymphocytes, infections
Phase 3Recruiting2026
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806 — cells, safety, microscopy, electron, scanning transmission, cyclophosphamide, stem cells, maintenance, multiple myeloma, lenalidomide, therapeutics, cell transplantation, stem cell transplantation, transplantation
Phase 3Active not recruiting2023
Study of ISB 2001 in Relapsed Refractory Multiple Myeloma (TRIgnite 1)
NCT05862012 — injections, multiple myeloma
Phase 1Recruiting2023
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and or Refractory Multiple Myeloma
NCT05704049 — administration, oral, powders, methylprednisolone, pharmaceutical preparations, dexamethasone, administration, intravenous, tablets, solutions, acetaminophen, multiple myeloma, therapeutics, diphenhydramine
Phase 2Active not recruiting2023
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide Bortezomib Dexamethasone (PVd) or Carfilzomib Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515 — dexamethasone, bortezomib, multiple myeloma, antibodies, monoclonal, lenalidomide, therapeutics
Phase 3Active not recruiting2023

LeadR Networks

Main global connection map